New drug combo targets tough adrenal cancer
NCT ID NCT05036434
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two drugs, pembrolizumab and lenvatinib, in 30 adults with advanced adrenal cortical carcinoma that has worsened after standard chemotherapy. The goal is to see if the combination can shrink or slow the cancer. Participants receive the drugs intravenously and by mouth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and lenvatinib (Lenvima)
What this could lead to
If it works, this could point toward a new treatment option for advanced adrenal cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group. The combination may not work or could cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea